Ottawa, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The global nanobiotechnology market size is calculated at USD 189 billion in 2025 and is expected to reach around USD 420.2 billion by 2034, growing at a CAGR of 9.37% for the forecasted period.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/6359
Key Takeaways
- The nanobiotechnology sector pushed the market to USD 172.81 billion by 2024.
- Long-term projections show a USD 420.2 billion valuation by 2034.
- Growth is expected at a steady CAGR of 9.37% in between 2025 to 2034.
- North America registered dominance in the market share by 42% in 2024.
- Asia Pacific is expected to be the fastest-growing region during 2025-2034.
- By application, the therapeutics segment held the largest revenue share of the market in 2024.
- By application, the instrumentation, consumables & services segment is expected to witness rapid expansion in the coming years.
- By platform/material type, the lipid nanoparticles (LNPS) & lipid-based systems segment led the nanobiotechnology market in 2024.
- By platform/material type, the exosomes & biological vesicles segment is expected to grow at a rapid CAGR in the upcoming years.
- By end-user/buyer type, the pharmaceutical & biotech companies segment dominated the market in 2024.
- By end-user/buyer type, the CDMOs/CMOs & manufacturing service providers segment is expected to grow rapidly during 2025-2034.
- By product type/offering, the nano-formulated therapeutics & vaccines segment was dominant in the market in 2024.
- By product type/offering, the software/analytics & characterization services segment is expected to witness the fastest growth in the studied years.
- By therapeutic area, the oncology segment registered dominance in the market in 2024.
- By therapeutic area, the ophthalmology & localized delivery segment is expected to grow fastest in the predicted timeframe.
Which Prominent Factors are Impacting the Nanobiotechnology?
The global nanobiotechnology market encompasses nanotechnology and biotechnology for the development of new materials, devices, and systems for biological & medical applications. The overall progression has been pushed by the growing healthcare demand, expanded R&D funding, technological integration (AI), and spurring applications in agriculture and environmental remediation. Recently, the market explored DNA origami nanodevices used in particular delivery of therapeutic siRNAs to inflamed gut areas.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
What are the Drivers in the Nanobiotechnology Market?
Firstly, a rise in the number of chronic issues, the world is demanding targeted therapies and tailored medicine, which promotes the incorporation of nanoparticles to deliver drugs or genetic material accurately to target cells. Alongside immersive government initiatives, specifically the U.S. National Nanotechnology Initiative (NNI), is facilitating significant financial and regulatory assistance. Whereas nanotechnology explores robustness and diversity in highly sensitive nanosensors and diagnostic tools.
What are the Ongoing Trends in the Nanobiotechnology Market?
- In November 2025, Pathway To Cures invested in SeraGene Therapeutics to revolutionise RNA and nanomedicine treatments for blood disorders.
- In October 2025, Nanoligent closed €12 million funding round to encourage the development of its oncology nanodrug.
- In September 2025, Cayman Chemical and Curapath partnered to facilitate broader access to PEG-free shielding lipids for lipid nanoparticles.
What is the Major Challenge in the Market?
Many players are facing limitations in achieving consistency in size, shape, and surface properties, with a shift from lab to large-scale and affordable manufacturing in the nanobiotechnology market. As well as ensuring nanomaterials' stability and integrating them effectively into applications is also creating a hurdle in the market progression.
Regional Analysis
How did North America Dominate the Nanobiotechnology Market in 2024?
With the 42% of biggest share, North America possess a huge and robust healthcare system, with raised expenditures on the same. Additionally, the region is promoting nanomaterials and nanofabrication, which allow novel applications, such as faster biosensors and advanced imaging. In the last years, the FDA approved numerous medical devices that use nanomaterials, such as spinal fusion implants with nano-surface technology (like Medtronic's Adaptix system) and nanocoated coronary stents (including Celonova Biosciences' COBRA PzF system). Recently, the University of Southern Mississippi has developed sprayable peptide amphiphile nanofibers that self-assemble into scaffolds, which mimic the body's extracellular matrix to enhance skin tissue repair.
How did the Asia Pacific Grow Notably in the Nanobiotechnology Market in 2024?
Asia Pacific is anticipated to expand rapidly in the coming era, due to the continuous immersive government investments, and the rising cases of cancer & neuro diseases. However, Chinese researchers are leveraging non-viral nanoparticle delivery systems for gene therapy and targeted drug delivery systems, particularly "nanorobots," created to treat complex issues with minimal systemic toxicity.
For instance,
- In September 2025, xFOREST Therapeutics Co., Ltd. and Axcelead Drug Discovery Partners, Inc. collaborated to focus on the progression of RNA structure-targeted small molecule therapeutics for multiple diseases.
Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting
Segmental Insights
By application analysis
Which Application Dominated the Nanobiotechnology Market in 2024?
By capturing a major share, the therapeutics segment registered dominance in the market in 2024. To resolve severe challenges in diverse diseases, the globe is involved in the exploration of nanocarriers, such as smart nanoparticles to respond to internal body stimuli, with the utilisation of nanomaterials to boost immunotherapy, and groundbreaking nanofiber scaffolds for wound healing. Recently, Hafnium Oxide Nanoparticles (Hensify) received EMA approval (and is in clinical trials in the US) for locally advanced soft tissue sarcoma.
On the other hand, the instrumentation, consumables & services segment will expand rapidly. Ongoing substantial efforts from researchers are providing printable, flexible biosensors, which employ core-shell cubic nanoparticles to track vital biomarkers and monitor liver cancer drugs in biological fluids. Along with this, startups, including INTA, are widely establishing lab-on-a-chip solutions for quicker biomolecular analysis using nanoacoustics and microfluidic channels. Also, Belgian startup PUXANO integrated nanotechnology and structural biology with AI for high-throughput protein design and characterization.
By platform/material type analysis
Why did the Lipid Nanoparticles (LNPS) & Lipid-Based Systems Segment Lead the Market in 2024?
The lipid nanoparticles (LNPS) & lipid-based systems segment was dominant in the nanobiotechnology market in 2024. Mainly, the market is emphasising the transformation of non-immunogenic options to PEG, such as in March 2025, Serina Therapeutics demonstrated preclinical data on their proprietary POZ-lipid technology, a PEG-free alternative. Novel lipids, especially the 4N4T series, are presenting increased mRNA translation effectiveness against SARS-CoV-2 variants (Delta and Omicron) as compared to developed options like SM-102.
However, the exosomes & biological vesicles segment is anticipated to register the fastest growth. The era is exploring biohybrid nanorobots by combining the natural biocompatibility and targeting abilities of exosomes with synthetic nanomaterials, like magnetic iron oxide or gold nanoparticles. Ongoing clinical trials, such as AGLE-102, an allogeneic-derived extracellular vesicle product, which is in Phase I/II clinical trials for the treatment of severe burns and a rare genetic skin disorder, known as Epidermolysis bullosa dystrophica, are assisting the comprehensive progress.
By end-user/buyer type analysis
What Made the Pharmaceutical & Biotech Companies Segment Dominant in the Market in 2024?
In 2024, the pharmaceutical & biotech companies segment captured the largest revenue share of the nanobiotechnology market. In the case of targeted drug delivery, these companies are using nanocarriers to cross the blood-brain barrier for treatments, and biodegradable nanocarriers in gene & RNA therapy. NanoTech Pharma, BioNano Solutions, QuantumNano, NanoMedica, etc., are specifically involved in nanomedicine.
Moreover, the CDMOs/CMOs & manufacturing service providers segment is predicted to witness rapid expansion. They are highly providing lipid nanoparticles, metallic nanoparticles, polymeric nanoparticles, with advanced techniques, like microfluidics, high-pressure homogenization, supercritical fluid processing, and solvent evaporation in the respective developments. Also, they are bolstering AI and ML for the prediction of equipment maintenance to modeling production outcomes and ensuring data integrity in compliance with GxP regulations.
By product type/offering analysis
Which Product Type/Offering Led the Nanobiotechnology Market in 2024?
The nano-formulated therapeutics & vaccines segment held the dominating share of the market in 2024. The latest advancements are driving the segmental expansion, such as nanogels loaded with immune-stimulating agents, including IL-15 superagonist complex, which is conjugated to T-cells, to majorly escalate the tumour-suppressing effect in mouse models. Recently, NanoViricides, Inc. announced its broad-spectrum antiviral drug candidate, NV-387, was cleared for Phase II clinical trials.
Although the software/analytics & characterization services segment will expand rapidly. The segment has been fueled by recent efforts, like Swiss startup NanoDecoder uses CMOS molecular electronic chips integrated with nanopore sensing and ML to store digital information in DNA for high-density product tracking and anti-counterfeiting. Inclusion of PiFM (Photothermal induced resonance Force Microscopy) is transforming nanoscale chemical imaging, offering deeper insights into material composition.
Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
By therapeutic area analysis
How did the Oncology Segment Dominate the Nanobiotechnology Market in 2024?
In 2024, the oncology segment accounted for the largest share of the market. Primarily, the companies are executing gold nanoparticles (nanorods) that reshape near-infrared light into localized heat to destroy cancer cells while activating immune responses. Immersive nanocarriers, like liposomes, polymers, and carbon nanotubes, are designed to respond to tumor microenvironments, further offering chemotherapy. Newly developed biosensors are encouraging ultrasensitive detection of cancer biomarkers at minimal concentrations.
Moreover, the ophthalmology & localized delivery segment is anticipated to witness rapid growth. Specifically, in 2025, many studies addressed their use in delivering antioxidants to the lens for non-surgical cataract treatment and anti-inflammatory agents for uveitis, with exploration of their ability to fuse with cell membranes and enhance corneal permeability. Besides this, players are widely reinforcing multi-functional nanomicelles and nanoemulsions for delivering anti-glaucoma drugs and anti-infective agents.
What are the Key Developments in the Nanobiotechnology Market?
- In December 2025, Zymosense launched nanosensors invented in Nigel Reuel's Iowa State lab, to track the enzymes' reactions in biotechnology, medicine, drug development, food production and other industrial applications.
- In November 2025, Nanobiotix announced breakthroughs for its next-wave Curadigm Nanoprimer platform.
- In September 2025, Mana.bio, a biotechnology company, unveiled Mina, the world's first large language model (LLM) built especially for lipid nanoparticles (LNPs).
- In March 2025, Korean biotech Mepsgen launched NanoCalibur GMP, an automated system for large-scale nanoparticle production, focused on preclinical and clinical drug development.
Nanobiotechnology Market Key Players List
- Moderna
- BioNTech
- Pfizer
- Acuitas Therapeutics
- Precision NanoSystems (PNS)
- Evonik/CordenPharma
- Lonza Catalent
- Thermo Fisher Scientific
- Merck/MilliporeSigma
- Nanobiotix
- Nanospectra Biosciences
- NanoString Technologies
- Bruker/Malvern Panalytical
- Abcam/Bio-reagent suppliers
- Cytiva (historically GE Life Sciences)
- Pall/Sartorius
- Exosome/EV specialists
- Celgene/BMS & other large pharma
- Specialist nano-CDMOs & startups
Browse more Insights from Towards Healthcare:
The quantum flex cell expansion system market is rapidly advancing on a scale, with expectations of accumulating hundreds of millions in revenue between 2026 and 2035.
The cell therapy solvent suspension tubing market is experiencing significant expansion, with projections indicating a revenue increase reaching several hundred million dollars by the end of the forecast period, spanning 2026 to 2035.
The global single-use sterile connectors for cell therapy market size is expected to be worth around USD 4.34 Billion by 2035, from USD 1.30 billion in 2025, growing at a CAGR of 12.8% during the forecast period from 2026 to 2035.
The cell and gene therapy market size touched US$ 27.02 billion in 2025, with expectations of climbing to US$ 33.5 billion in 2026 and hitting US$ 232.22 billion by 2035, driven by a CAGR of 24% over the forecast period.
The global biosimilar contract manufacturing market size is calculated at US$ 9.22 billion in 2025, grew to US$ 10.96 billion in 2026, and is projected to reach around US$ 52.23 billion by 2035. The market is expanding at a CAGR of 18.94% between 2026 and 2035.
The global nanoparticle synthesis system market size is calculated at US$ 0.7 billion in 2024, grew to US$ 0.78 billion in 2025, and is projected to reach around US$ 2.05 billion by 2034. The market is projected to expand at a CAGR of 11.34% between 2025 and 2034.
The global intranasal drug delivery devices market size is estimated at US$ 1.74 billion in 2024, is projected to grow to US$ 1.91 billion in 2025, and is expected to reach around US$ 4.54 billion by 2034. The market is projected to expand at a CAGR of 10.04% between 2025 and 2034.
The global lipid nanoparticle manufacturing market size is calculated at USD 400 in 2024, grew to USD 475 million in 2025, and is projected to reach around USD 2243 million by 2034. The market is expanding at a CAGR of 18.9% between 2025 and 2034.
The global lipid nanoparticles market size is calculated at USD 1.04 billion in 2024, grew to USD 1.18 billion in 2025, and is projected to reach around USD 3.84 billion by 2034. The market is expanding at a CAGR of 13.97% between 2025 and 2034.
The global lipid nanoparticle raw materials market size is projected to reach USD 522.01 million by 2035, expanding from USD 300.72 million in 2025, at an annual growth rate of 5.67% during the forecast period from 2025 to 2035.
Segments Covered in the Report
By Application
- Therapeutics: Drug & RNA delivery
- LNPs for mRNA/siRNA, targeted chemotherapeutic nanoparticles, sustained-release nanoformulations
- Diagnostics & Biosensors (in-vitro & point-of-care)
- Nanoparticle labels, lateral-flow enhancements, plasmonic/SPR sensors
- Imaging & Theranostics (nano-contrast agents, gold nanoshells)
- Vaccines & Adjuvant Platforms (nano-adjuvants, LNP vaccines)
- Regenerative Medicine & Tissue Engineering
- Agricultural & Environmental Nano-bio applications
- Instrumentation, Consumables & Services (supporting nanobiotech R&D/manufacturing)
By Platform / Material Type
- Lipid nanoparticles (LNPs) & lipid-based systems
- Polymeric nanoparticles/PLGA, PEGylated carriers
- Inorganic nanoparticles (gold, silica, iron oxide)
- Nanocrystals/nanosuspensions
- Exosomes & biological vesicles
- Dendrimers/hybrid nanostructures
- Quantum dots & advanced labels
By End User/Buyer Type
- Pharmaceutical & Biotech Companies
- Clinical Laboratories & Diagnostics Firms
- Academic & Research Institutions
- CDMOs/CMOs & Manufacturing Service Providers
- Hospitals & Imaging Centers
By Product Type/Offering
- Nano-formulated therapeutics & vaccines
- Nano-enabled diagnostics & kits
- Instruments & analytical platforms (microscopy, nanoparticle characterization)
- Manufacturing consumables (lipids, excipients, single-use assemblies)
- Software/analytics & characterization services
By Therapeutic Area
- Oncology
- Infectious disease/Vaccines
- Rare diseases & genetic disorders (RNA therapies)
- Neurology/CNS delivery
- Cardiometabolic & other
- Ophthalmology & localized delivery
By Region
- North America
- U.S.
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/6359
Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web: https://www.towardshealthcare.com
Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
